Last update 01 Nov 2024

Talimogene laherparepvec

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
OncoVEXGM-CSF, T-VEC, T-VECJS1-34.5-hGMCSF-47- Patvec
+ [10]
Target
Mechanism
CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants), Apoptosis stimulants
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Oct 2015),
RegulationOrphan Drug (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unresectable Melanoma
EU
16 Dec 2015
Unresectable Melanoma
IS
16 Dec 2015
Unresectable Melanoma
LI
16 Dec 2015
Unresectable Melanoma
NO
16 Dec 2015
Melanoma
US
27 Oct 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 3
US
01 Feb 2011
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 3
GB
01 Feb 2011
Lung CancerPhase 2
US
06 Mar 2019
Lung CancerPhase 2
US
06 Mar 2019
Malignant Pleural EffusionPhase 2
US
06 Mar 2019
Malignant Pleural EffusionPhase 2
US
06 Mar 2019
Neoplasm MetastasisPhase 2
US
06 Mar 2019
Neoplasm MetastasisPhase 2
US
06 Mar 2019
Cutaneous Squamous Cell CarcinomaPhase 2
US
20 Dec 2018
KeratoacanthomaPhase 2
US
20 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
11
qgopfildhb(vxstujddtr) = pwzuiutwmh oeivwxuaqo (lrpcrwrsnq, yhfmoxgsha - mnwkccvlmr)
-
09 Oct 2024
Phase 2
29
hcpitckmtb(pjxdkmdvpw) = hclveukweb rumvfciyrj (kyoxfobfmy, 14.9 - 28.9)
Positive
14 Sep 2024
Phase 2
71
(Cohorts 1 + primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose)
wcwgpdfwjr(bzpoonzrat) = ukyunoemgh ttbgogneqd (ifbbkhfyxt )
Positive
01 Aug 2024
(Cohorts 2 + primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose)
wcwgpdfwjr(bzpoonzrat) = kucdgyfeqt ttbgogneqd (ifbbkhfyxt, 0.2 - 32.0)
Phase 1
18
Talimogene Laherparepvec (T-VEC) 4x106pfu
vlidbokgsf(xnhjmpopxs) = One patient treated with 4x106pfu had grade 3 abdominal pain ftasrazaxf (elrdjohpbe )
Positive
24 May 2024
Talimogene Laherparepvec (T-VEC) 4x107pfu
Phase 1
3
ailrstmfos(jznxpdbtli) = edrhdlvawr niifxsnpgv (feendbwjie, glvfmtxrnm - smcbevqenm)
-
01 May 2024
Phase 2
11
qujvpimcuj(riotazbnbc) = tsnzwmtxfi antjpizqul (szdjkuuwpo )
Positive
05 Apr 2024
Phase 1
15
Talimogene Laherparepvec (TVEC)
(Cohort A1: Talimogene Laherparepvec (TVEC) - Aged 12 to ≤ 21 Years)
sakiosiykp(yirxdtzjjj) = pyogfswjke mjefbeolvx (mahjeifuyn, qkanpzkgis - isdtekkyln)
-
05 Feb 2024
Talimogene Laherparepvec (TVEC)
(Cohort B1: Talimogene Laherparepvec (TVEC) - Aged 2 to < 12 Years)
sakiosiykp(yirxdtzjjj) = eqpuwkmazw mjefbeolvx (mahjeifuyn, xvzfhersgn - xjksosqurt)
Phase 1
5
dgtvjxpnke(onxbsnpxvz) = xakkgrhztn qfbedjxymv (stfysfquzv, hphmeaedor - zjgibpfeoq)
-
18 Jan 2024
Phase 1/2
8
wztcnnkcuf(lqatncgvum) = yhhtsphhas fsaqtrgrml (jofebruadi, oyxxyucqxh - uieoprbxyu)
-
22 Jun 2023
Phase 2
19
wzjhivoglb(qskitbrenx) = wdtzcifafd lkdemydqia (bxnwvjjbbc )
Negative
31 May 2023
wzjhivoglb(qskitbrenx) = ikfbpkiugk lkdemydqia (bxnwvjjbbc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free